A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE)

See ANZCTR for full trial details >

 

Trial Summary:

To evaluate the efficacy and tolerability of dual blockade combination durvalumab and tremelimumab with platinum-pemetrexed in patients with metastatic NSCLC (T790+ve or T790M-ve) who progressed on EGFR- Tyrosine Kinase Inhibitors. 

Supported By:

AstraZeneca

Eligibility:

Adults with relapsed non-squamous NSCLC with EGFR mutation with or without T790M mutation. 

Registration ID:

ACTRN12618001742268

Participation:

Australia & Taiwan

Status:

Closed

Activation Date:

Q1 2019

Chairs:

A/Prof Chee Lee (St George Hospital)

Contact:

illuminate.study@sydney.edu.au